Literature DB >> 9042267

K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers.

J C Lee1, S T Wang, M D Lai, Y J Lin, H B Yang.   

Abstract

Mutations in the K-ras gene were found to be of predictive value in the clinical outcome of non-small cell lung cancers, but its role in predicting the survival of colorectal cancer patients is still inconclusive. Point mutations in codon 12 or 13 of K-ras gene were analyzed in 64 colorectal cancers composing 4 Dukes' stage. A, 34 stage B, 21 stage C and 5 stage D. DNA extracted from the paraffin-embedded tissues of the 64 patients was amplified with the polymerase chain reaction and subsequently analyzed by direct cycle sequencing. Thirteen of sixty-four (20%) resected colorectal cancer specimens were found to have K-ras gene mutation at either codon 12 or 13. Log rank tests found that K-ras gene mutation and Dukes' stage were associated with patients' survival. When stratified by Dukes' stage, the patients with mutated K-ras genes in the stratum of stage A or B were found to have shorter survival times than those without mutated K-ras genes (P = 0.003), but this was not the case in the stratum of stages C and D. The relative risk of mortality in the stratum of stage A or B was 7.74 (95% confidence interval: 1.72-34.89) by Cox regression analysis. We thereby conclude that K-ras gene mutation is a usefull predictor of the survival of early stage colorectal cancers.

Entities:  

Mesh:

Year:  1996        PMID: 9042267

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics.

Authors:  Janine G Einspahr; Maria Elena Martinez; Ruiyun Jiang; Chiu-Hsieh Hsu; Asif Rashid; Achyut K Bhattacharrya; Dennis J Ahnen; Elizabeth T Jacobs; P Scott Houlihan; C Renee Webb; David S Alberts; Stanley R Hamilton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

Review 2.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

3.  The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma.

Authors:  A Conlin; G Smith; F A Carey; C R Wolf; R J C Steele
Journal:  Gut       Date:  2005-04-20       Impact factor: 23.059

4.  APC and K-ras gene mutation in aberrant crypt foci of human colon.

Authors:  P Yuan; M H Sun; J S Zhang; X Z Zhu; D R Shi
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

Review 5.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

6.  Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.

Authors:  Fortunato Ciardiello; Sabine Tejpar; Demetris Papamichael
Journal:  Target Oncol       Date:  2009-11-14       Impact factor: 4.493

7.  Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis.

Authors:  Mandayam O Nandan; Beth B McConnell; Amr M Ghaleb; Agnieszka B Bialkowska; Hongmiao Sheng; Jinyi Shao; Brian A Babbin; Sylvie Robine; Vincent W Yang
Journal:  Gastroenterology       Date:  2007-10-17       Impact factor: 22.682

8.  p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.

Authors:  Emanuela Guerra; Alessia Cimadamore; Pasquale Simeone; Giovanna Vacca; Rossano Lattanzio; Gerardo Botti; Valentina Gatta; Marco D'Aurora; Barbara Simionati; Mauro Piantelli; Saverio Alberti
Journal:  BMC Cancer       Date:  2016-08-18       Impact factor: 4.430

Review 9.  KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.

Authors:  Ahmad D Siddiqui; Bilal Piperdi
Journal:  Ann Surg Oncol       Date:  2009-11-20       Impact factor: 5.344

10.  Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer?

Authors:  Annette Torgunrud Kristensen; Johan N Wiig; Stein G Larsen; Karl-Erik Giercksky; Per O Ekstrøm
Journal:  BMC Cancer       Date:  2008-07-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.